Q2 FY2026 EarningsQ2 FY26 outperformed consensus expectations across all major financial metrics: revenue reached $707.3M vs. $688.8M expected, while diluted EPS of $4.25 beat the $3.99 mean estimate. The top-line beat was primarily driven by explosive 48.1% YoY growth in the Metabolic therapeutic segment. Net income was further supported by a favorable tax rate of 20.0% (vs. 22.2% expected) and aggressive share repurchases totaling $294.7M during the quarter. Backlog increased to $3.01B, with management expecting ~$1.96B to convert to revenue over the next twelve months.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Medpace(MEDP) the Revenue is 707.33 M (+17.24%), Beat estimate;the EBIT is 146.82 M (+4262 times%), Beat estimate;the EPS is 4.25 (+37.1%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.71B17.24%
0.69B14.17%
+0.02B3.07%
EBITExceed expectations
0.15B426218.23%
0.14B405319.11%
+0.01B20,899.12%
EPSExceed expectations
4.2537.10%
3.988428.66%
+0.26168.44%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf